FreeGuest Editorial Lung-MAP: A five-year recap on the first master protocol trial in cancer research February 21, 2020Vol.46 No.08By Roy S. Herbst, Lyudmila Bazhenova, Joel Neal and Saiama N. Waqar
Conversation with The Cancer LetterFree Thomas Lynch lists his areas of emphasis at the Hutch:Solid tumors, immuno-oncology, big data, microbial involvement January 31, 2020Vol.46 No.5By Paul Goldberg
Free The price of smoking for a lifetime is lowest in the South, highest in the NortheastHere are the numbers January 24, 2020Vol.46 No.04By Alexandria Carolan
Conversation with The Cancer LetterFree Robert Winn holds forth on big data, bench-to-community research—and being the only African American director of an NCI-designated cancer center January 17, 2020Vol.46 No.03By Paul Goldberg
FreeGuest Editorial Immunotherapy, precision medicine in lung cancer drive sharp decline in cancer mortality overall January 08, 2020Vol.46 No.02By Otis W. Brawley
FreeGuest Editorial FDA e-cigarette flavoring ban leaves a bad taste“Trump eroding role of science in government” January 03, 2020Vol.46 No.01By Alan Blum
Drugs & TargetsFree FDA issues draft guidance to foster pediatric oncology product development December 13, 2019Vol.45 No.46
Drugs & TargetsFree FDA approves Avsola for same indications as Remicade December 13, 2019Vol.45 No.46
